EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of non‐small cell lung cancer (NSCLC) patients with EGFR‐TKI sensitizing mutations over traditional platinum‐based chemotherapy [2, 3, 4, 5, 6].